PARIS (dpa-AFX) - IGM Biosciences, Inc. (IGMS) said the company's
collaboration agreement with Sanofi to create and develop IgM agonist antibodies
will now focus exclusively on immunology/inflammation targets. IGM will retain
global rights to its technology related to the oncology targets nominated by
Sanofi.

'We are very pleased with our collaboration with Sanofi and with the preclinical
data that we have generated in both the immunology/inflammation and the oncology
portions of the collaboration,' said Fred Schwarzer, CEO of IGM Biosciences.

Shares of IGM Biosciences are up 6% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX